Protagonist Therapeutics
PTGXProtagonist Therapeutics is an integrated biotechnology company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapies.
Earnings
Next report
Aug 5, 2026 (In 1 week)Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
By net margin
Profile
Protagonist Therapeutics is an integrated biotechnology company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapies. The company focuses on creating targeted medicines for biologically validated pathways in inflammation, immunology, hematology, and metabolic diseases. Its core value proposition lies in developing oral and injectable alternatives to existing parenteral biologic treatments to improve patient adherence and clinical outcomes.
A platform-driven innovator specializing in converting injectable biologic pathways into oral peptide therapeutics, supported by high-profile global pharmaceutical partnerships.
Questions, answered.
- What is Protagonist Therapeutics's market cap?
- Protagonist Therapeutics (PTGX) has a market capitalization of $8.7B and trades on NASDAQ.
- What is Protagonist Therapeutics's revenue and profitability?
- Protagonist Therapeutics generated $74.1M in trailing twelve-month revenue with a net loss of $114.7M, representing a net margin of -154.9%, with free cash flow of $316.6M. These figures are based on the Q1 2026 filing.
- Who are Protagonist Therapeutics's competitors?
- Protagonist Therapeutics's key competitors include Incyte, Eli Lilly and Company, Amgen, and others. These companies compete in similar markets and product categories.
- Who does Protagonist Therapeutics partner with?
- Protagonist Therapeutics's notable partners include Janssen Biotech, Inc., Takeda Pharmaceuticals, Inc..
- Where is Protagonist Therapeutics headquartered?
- Protagonist Therapeutics is headquartered in United States of America and employs approximately 124 people. It has been publicly traded since 2016.
